Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project
International Journal of Epidemiology · 17.04.2026 · 55 (3)
DOI: 10.1093/ije/dyag064 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Epidemiology, online erschienen am 20.05.2026. Verfasst von Lois Riobó-Mayo und 27 weiteren Autor:innen. Beteiligte Einrichtung: ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Early Detection of Cancer, Pancreatic Neoplasms. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Fondazione Regionale per la Ricerca Biomedica (FRRB), Executive Agency for Higher Education, Research, Development and Innovation Funding, Instituto de Salud Carlos III (ISCIII).
Abstract (Originalsprache)
Background
Early detection is critical in pancreatic ductal adenocarcinoma (PDAC)—one of the most lethal malignancies due to its typically late diagnosis.
Methods
In this study, we aimed to validate an epidemiological risk score (ERS) designed to identify individuals at increased risk of developing PDAC prior to the use of imaging or other diagnostic procedures. The ERS was constructed through a meta-analysis of 24 well-established epidemiological risk factors. We applied this score to a prospective cohort of 178 high-risk individuals with a family history of PDAC within the IMAGene project (ClinicalTrials.gov registration code: NCT06334458). To evaluate the predictive value of the ERS, all participants underwent whole-body or abdominal magnetic resonance imaging (MRI) and the findings were classified according to the Oncologically Relevant Findings Reporting and Data System criteria to identify and categorize lesions based on their malignant potential. External validation was conducted by using a subset of the UK Biobank (UKB) cohort (≈300 000 individuals), among whom 1648 were diagnosed with PDAC.
Results
Higher ERS values were associated with the presence of potentially malignant lesions on MRI. Both pancreatic and extra-pancreatic malignant lesions were more frequent among individuals with higher ERS scores (P = .01 and P = .02 respectively) compared with controls. External validation in PDAC cases within the UKB cohort confirmed these associations.
Conclusion
Our findings support the integration of the ERS as a feasible, low-cost tool for PDAC risk stratification, with the potential to facilitate earlier detection and improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
- Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, 08908, Spain.
- Doctoral Program in Medicine and Translational Research, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, 08907, Spain.
- Hereditary Cancer Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, 28029, Spain.
- Medical Oncology Department, Catalan Institute of Oncology, Badalona, Barcelona, 08916, Spain.
ORCID-Profile: Lois Riobó-Mayo, Alex Teulé, Serena Oliveri, Nicola Fazio, Mireia Obón-Santacana, Victor Moreno
Förderung
- Fondazione Regionale per la Ricerca Biomedica (FRRB)
- Executive Agency for Higher Education, Research, Development and Innovation Funding
- Instituto de Salud Carlos III (ISCIII)
- Programa FORTALECE del Ministerio de Ciencia e Innovación'
- Horizon Europe Mission Cancer project DISCERN
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)
- AECC Scientific Foundation
- French National Agency for Research (ANR)
Zitieren
APA
Riobó-Mayo, L., Salvador, L., Teulé, A., Guinó, E., Layos, L., Oliveri, S., Cincidda, C., Ongaro, G., Accornero, C. A., Cella, C. A., Gervaso, L., Fazio, N., Summers, P. E., Petralia, G., Canivet, C., Bournet, B., Buscail, L., Roman, A., Balacescu, L., …, & Moreno, V. (2026). Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project. International Journal of Epidemiology, 55(3). https://doi.org/10.1093/ije/dyag064
Vancouver
Riobó-Mayo L, Salvador L, Teulé A, Guinó E, Layos L, Oliveri S, et al. Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project. International Journal of Epidemiology. 2026;55(3). doi:10.1093/ije/dyag064
BibTeX
@article{RiobMayo2026,
author = {Riobó-Mayo, Lois and Salvador, Lluis and Teulé, Alex and Guinó, Elisabet and Layos, Laura and Oliveri, Serena and Cincidda, Clizia and Ongaro, Giulia and Accornero, Chiara A and Cella, Chiara Alessandra and Gervaso, Lorenzo and Fazio, Nicola and Summers, Paul E and Petralia, Giuseppe and Canivet, Cindy and Bournet, Barbara and Buscail, Louis and Roman, Andrei and Balacescu, Loredana and Trifa, Adrian and Catana, Andreea and Pop, Florina and Balacescu, Ovidiu and Przybyłowicz, Patrycja and Taryma-Lesniak, Olga and Wojdacz, Tomasz K and Obón-Santacana, Mireia and Moreno, Victor},
title = {Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project},
journal = {International Journal of Epidemiology},
year = {2026},
volume = {55},
number = {3},
doi = {10.1093/ije/dyag064}
}
EUVIMED